TransCode Therapeutics, Inc. RNAZ
At closeNov 5, 2026, 4:00 PM EST
After hours · Nov 5, 4:00 PM ET
- YTD
- -77.89%
- 1 year
- -84.22%
- Market cap
- 25.57M
- EPS (ttm)
- -52.06
- Shares out
- 696.25K
- Forward P/E
- -5.97
- YTD return
- -77.89%
- 1-year return
- -84.22%
- Volume
- 20.41K
- Avg volume
- 54.12K
- Open
- 1.63
- Previous close
- 1.60
- Day's range
- 1.53 – 1.67
- 52-week range
- 1.50 – 12.60
- Beta
- 0.65
- Analysts
- Buy
- Price target
- 20.00 (+1224.5%)
- Earnings date
- Aug 14, 2024
6M -6.01 (-79.92%)
Key statistics
- Enterprise value
- 2.74M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 1.37
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -8.54M
- Total cash
- 3.35M
- Total debt
- 227.25K
- Return on equity
- -1048.70%
- Short % of float
- 4.31%
- 50-day average
- 13.50
- 200-day average
- 20.41
Analyst view
Consensus: buy
- Strong buy1
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 14, 2024
Expected Aug 14, 2024. Consensus EPS estimate -3.21.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -16.17 | -5.28 | +10.89 | +67.35% |
| Aug 14, 2024 | Jun 1, 2024 | -19.14 | — | — | — |
| Aug 14, 2024 | Jun 1, 2024 | -19.14 | -24.42 | -5.28 | -27.59% |
| May 15, 2024 | Mar 1, 2024 | -23.10 | -21.45 | +1.65 | +7.14% |
| May 15, 2024 | Mar 1, 2024 | -23.10 | — | — | — |
| Mar 29, 2024 | Dec 1, 2023 | -10.80 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 24, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 6, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 29, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 16, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About TransCode Therapeutics, Inc.
TransCode Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer. The company's lead therapeutic candidate comprises TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and two indication agnostic programs; TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. has strategic collaboration agreement with The University of Texas M. D. Anderson Cancer Center. The company was incorporated in 2016 and is based in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- transcodetherapeutics.com
News
TransCode Therapeutics' Board Initiates A Formal Strategic Process To Evaluate Opportunities Designed To Maximize The Value Of The Company And Its Oncology Portfolio, Including Its Lead Product Candidate, TTX-MC138 
TransCode Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process Intended to Maximize Value of TTX-MC138 and its Oncology Portfolio 
TransCode Therapeutics Presents Phase 1a Clinical Data for TTX-MC138 at ESMO Congress 2026 
TransCode Therapeutics to Present Phase 1a Clinical Trial Data for TTX-MC138 at ESMO Congress 2026 
Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer 
Natera, TransCode Therapeutics Partnering To Support Enrollment For TransCode’s Phase 2a Study Of TTX-MC138 In Participants With Colorectal Cancer 
Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer - TransCode Therapeutics Announces Updated Clinical Data From Phase 1a Clinical Trial Of TTX-MC138, Reinforcing Evidence Of Antitumor Activity In Heavily Pretreated Patients With Advanced Solid Tumors
TransCode Reports Continued Disease Stabilization and Extended Treatment Duration with TTX-MC138 in Ongoing Phase 1a Clinical Trial Follow-Up 
TransCode Therapeutics Announces Australia Acceptance Of Patent application, Japan's Issuance Of Notice Of Allowance For Its RNA-Based Therapeutic Platform Technologies
Your note
Sign in to keep a note on RNAZ — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DUDLEY ROBERT MICHAEL | Chief Executive Officer | Purchase | Sep 27, 2023 | 180,262 |
| FITZGERALD THOMAS A | Chief Financial Officer | Purchase | Sep 27, 2023 | 56,318 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Geode Capital Management, LLC | 0.53% | 3,690 | 13.21K | Sep 29, 2024 |
| Private Capital Management LLC | 0.35% | 2,445 | 8.75K | Sep 29, 2024 |
| Sheets Smith Wealth Management | 0.22% | 1,519 | 5.44K | Sep 29, 2024 |
| Jane Street Group, LLC | 0.17% | 1,204 | 4.31K | Sep 29, 2024 |
| Captrust Financial Advisors | 0.07% | 492 | 1.76K | Sep 29, 2024 |
| Morgan Stanley | 0.04% | 303 | 1.08K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.42% | 2,906 | 10.40K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.17% | 1,180 | 4.22K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.10% | 686 | 2.46K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.00% | 33 | 118 | Oct 30, 2024 |